

Integrated Diagnostics Holdings PLC

21 June 2023

IDH appoints new Chief Financial Officer and Strategic Investment Officer

21 June 2023

(Cairo and London) - Integrated Diagnostics Holdings ("IDH," "the Group," or "the Company"), a leading prodiagnostics services with operations in Egypt, Jordan, Nigeria and Sudan, announces the appointment of Al Gebeily as Group Chief Financial Officer, effective 15 August 2023. His appointment will follow the departure long-term VP Finance and Strategies and Group Chief Financial Officer, Omar Bedewy, on 30 June 2023. Bed been with IDH since 2016 and has played a vital role in the Company's growth and expansion in recent years. IDI excited to announce the appointment of Sherif El Etreby, who will fill the role of Group Strategic Investment effective 15 August 2023.

During the transition, Bedewy, along with the rest of IDH's management team, is committed to ensuring an handover of responsibilities, remaining diligent in the Company's transitional phase until El Gebeily effectively a his role as Group Chief Financial Officer. Following Bedewy's departure, Ahmed Sileem will fill the position of Chief Financial Officer until El Gebeily fills the role on 15 August 2023. Sileem currently serves as Regional F Controller at IDH and has been with the Company since 2012.

El Etreby, filling the new role of Group Strategic Investment Officer, will be responsible for developing and direct Group's strategy pillars and long-term outlook, identifying potential opportunities for business expansion. T position was created in line with IDH's continuous efforts to identify and maximise long-term growth across its cur potential markets.

Dr. Hend El Sherbini, Group Chief Executive Officer, commented: "On behalf of IDH's Board of Direct management team, I would like to thank Omar for his invaluable contributions to the Company over the past seve and his pivotal role in our growth story. Omar has been an exceptional leader within IDH's walls since he first j 2016 and has helped navigate the Company through some of its most challenging times. We wish him all the be future endeavours.

"In the coming weeks, and along with the rest of the management team, I will prioritize the smooth continuation of business operations, as well as safeguard an effective handover to our next CFO, who will surely continue to pivotal a role as Omar has in the past years. I am excited at the level of experience that both additions management team bring with them. Both Ahmed and Sherif are experienced executives with unique skills and example and I have the utmost confidence in their ability to further guide IDH in its future growth plans and their ability within the IDH family. The addition of the Strategic Investment Officer role to our team marks a new era for II further reaffirms our commitment to delivering strategic growth wherever possible." Dr. Hend added.

Commenting on his departure, Omar Bedewy, Chief Financial Officer, said: "I am truly grateful for the injourney I have had during my tenure at IDH. It has been an absolute privilege working alongside a talented and deteam throughout the years. Together, we have accomplished remarkable milestones that have cemented our post a leading healthcare provider in all our markets. Over the coming weeks, I remain committed to seeing the full hof my roles and responsibilities to my successor to ensure continued success for IDH under his guidance.

"As I move on from my role, I want to express my heartfelt wishes for IDH's continued success and future growth the utmost confidence in the organization's ability to navigate the evolving healthcare landscape and continue great strides in the future. I will continue to follow IDH's progress and celebrate its achievements with immense providing lives and remaining on the front lines providing quality healthcare in the region." He added.

Ahmed El Gebeily Bio

El Gebeily is a senior executive finance director with nearly three decades of experience and a successful track r business start-ups in various international and local settings, including construction, building material industries others. He currently serves as the Chief Financial Officer at Egyptian Industrial Investment Group.

His previous experiences include Senior Executive Finance Director at Egyptian Steel Group, Regional Finance at Lafarge Middle East and Africa, and Head of Finance for New Projects at Orascom Industries - Cement Division to these roles, El Gebeily held several positions with Kharafi Group, where he was stationed in several controlleding Albania, Syria, South Africa and Mozambique.

He boasts a unique set of skills and experience, including experience in company management, holding restructuliquidation, designing accounting systems, ERP implementation, and company registration processes.

During his tenure, he gained strong exposure in acquisitions, due diligence, post-purchase audits, joint management, sale and purchase agreements (SPA), shareholders loan agreements, as well as the management setup of full Financial Shared Services Centre (FSSC), both locally and regionally.

El Gebeily's skills also include project financial management, costing and contract negotiation, and closure. El Gebeily is skills also include project financial management, costing and contract negotiation, and closure. El Gebeily is skilled at knowledge transferring, team building, and training future generations for leadership position.

Sherif El Etreby Bio

El Etreby is a seasoned financial executive with over 25 years of experience in the financial field, boasting significant roles and major achievements in banking institutions for 10 years. He currently serves as the Ser President of Investments at Egyptian Industrial Investment Group.

El Etreby's previous experiences include nine years as the Senior Planning Executive at Egyptian Steel Group, as a member of the founding team of Egyptian Cement Company during the same period. Prior to those roles, he see the Regional Controller for Special Projects - Middle East and Africa at Lafarge, as well as Deputy Regional E Controller for North Africa and Head of Planning at Orascom Construction - Cement Sector.

He has been involved in major syndication loans facilities, acquisitions, and divestments in the cement and steel in the Middle East and Africa, including the acquisition of Lafarge to Orascom Construction Industries - Cement S 2008. He was also involved in the sell down of the founder's stack in Egyptian Steel Group to Al Ezz Dekheila S in 2021.

-Ends-

About Integrated Diagnostics Holdings (IDH)

IDH is a leading diagnostics services provider in the Middle East and Africa offering a broad range of pathologous radiology tests to patients in Egypt, Jordan, Nigeria and Sudan. The Group's core brands include Al Borg, Al Borand Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and E (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as internationally recognised accreditations for its portfolio of over 2,000 diagnostics tests. From its base of 552 brand 31 December 2022, IDH served over 8.7 million patients and performs more than 32.7 million tests in 2022. continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable plat efficient expansion. Beyond organic growth, the Group's expansion plans include acquisitions in new Middle African, and East Asian markets where its model is well-suited to capitalise on similar healthcare and consume and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015 with a secondary listing on the Since May 2021 (ticker: IDHC.CA). Learn more at idhcorp.com.

Contact Nancy Fahmy Investor Relations Director

T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 | nancy.fahmy@idhcorp.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

BOAPPUAGQUPWGUG